Real-world clinical study of Trastuzumab biosimilar (Zercepac) and Pertuzumab (Perjeta) in combination with chemotherapy for neoadjuvant treatment of HER-2-positive breast cancer
Asian J Surg. 2024 Mar 23:S1015-9584(24)00493-7.
doi: 10.1016/j.asjsur.2024.03.063.
Online ahead of print.
1 Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, 014040, Inner Mongolia, China.
2 Department of Breast Surgery, Baotou Cancer Hospital, Baotou, 014030, Inner Mongolia, China.
3 Department of Breast Surgery, Baotou Cancer Hospital, Baotou, 014030, Inner Mongolia, China; Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, 014040, Inner Mongolia, China. Electronic address: zhujingjunzjjne@126.com.